-+ 0.00%
-+ 0.00%
-+ 0.00%

Prostatype Genomics FY26 H1 EBITDA loss narrows to SEK 16.38 million; net sales rise 85.77% to SEK 457,000

PUBT·08/31/2026 07:33:26
Listen to the news
Prostatype Genomics FY26 H1 EBITDA loss narrows to SEK 16.38 million; net sales rise 85.77% to SEK 457,000
  • Prostatype Genomics posted first-half net sales of SEK 457,000, up 85.77% year over year.
  • EBITDA loss narrowed to SEK 16.38 million from SEK 18.97 million a year earlier.
  • Operating cash outflow improved to SEK 14.18 million, while total cash flow swung to an outflow of SEK 8.68 million.
  • Earnings per share came in at SEK -0.29, improving from SEK -1.42 in the year-ago period.
  • CEO Fredrik Rickman cited a published U.S. validation study, while Medicare reimbursement work continued following an in-person meeting in Q2.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prostatype Genomics AB published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.